AI For Pharma Growth

Most pharma companies are racing to apply AI across drug discovery, development and commercialisation, but many of those efforts will fail for one simple reason: the data underneath is not good enough. In this episode, Dr Andree Bates speaks with Lisa Downey, CEO of DrugBank, about why trusted, structured biomedical intelligence is the foundation pharma AI cannot succeed without.Lisa explains how DrugBank has spent 20 years building and continuously curating a biomedical knowledge layer across drugs, targets, diseases and trials. With more than 156 million structured data points and over 60,000 academic citations, DrugBank is not just another dataset. It is a continuously maintained reference system designed so AI can reason over biomedical knowledge with traceability and trust.The conversation explores why most pharma AI projects fall short. Lisa argues the blocker is rarely the model. Instead, teams hit the wall because internal data lakes are not harmonised, licensed third-party data may not be AI-ready, and public data sources are incomplete or not maintained for enterprise use. Brilliant ML teams then spend most of their time cleaning and reconciling data instead of creating real scientific or commercial value.Lisa also breaks down what pharma buyers should test before trusting any AI vendor: interoperability, harmonisation, evidence lineage and continuous validation. She explains why human pharmaceutical expertise still matters, introducing DrugBank’s “human over the loop” approach, where experts set scientific boundaries, validation criteria and judgement so AI can scale inside trusted guardrails.Topics CoveredWhy most pharma AI projects fail before they scaleData quality as the foundation of trustworthy AIDrugBank’s 20 years of curated biomedical intelligenceInternal data lakes, third-party data and public data limitationsWhy hallucinations often start upstream of the modelHow to evaluate data quality: interoperability, harmonisation, lineage and validationHuman over the loop vs human in the loopWhy defensible AI needs traceable sourced factsThe difference between confident AI and grounded AIWhy proprietary context matters more than raw dataEularis helps pharma and biotech leaders turn AI activity into board-defensible strategy and measurable commercial outcomes.If your organisation has plenty of AI in motion but very little that moves the commercial needle in a way the board can see, start with our 10-Day AI Diagnostic Sprint. It’s a focused diagnostic that surfaces what’s actually broken and what’s blocking results, before you invest in a larger strategy effort.The Sprint diagnoses the problem. The AI Strategic Blueprint that follows is where we build the board-defensible strategy and plan.Details at eularis.com.AI platforms and tools solve specific problems. Strategy makes sure you’re solving the right ones, in the right order. If you want help mapping priorities as you evaluate what to roll out next, send me a LinkedIn DM starting with ‘PRIORITIES’ and two lines: what’s already in flight, and the decision you’re trying to make next.About the PodcastAI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.Dr. Andree Bates LinkedIn | Facebook | X

AI capability has never been higher, yet most pharma AI programmes are still failing to create measurable business impact. In this solo episode, Dr Andree Bates breaks down why many pharma and biotech AI strategies are “broken before they even begin” and what a real AI strategic blueprint needs to include if you want adoption, scale, and outcomes, not just impressive pilots.Dr Andree explains the core paradox: AI can now synthesise literature at speed, accelerate discovery, and outperform human experts in specific tasks, but the business results are often disappointing because the failure is rarely technical. It is strategic. She describes the “technical obsession trap”, where organisations spend months optimising models and benchmarking competitors while adoption remains low and teams are not operationally ready to act on the outputs.She outlines three common failure modes:Innovation Theatre, where disconnected pilots never compound into enterprise valueCompetitor benchmarking, where companies copy use cases that do not fit their contextTechnology first strategy, where tools are bought before priorities are definedFrom there, she maps what a strong pharma AI blueprint must cover: grounding in business objectives, end to end deployment architecture (data, governance, capability, change), leadership and culture, rigorous financial modelling tied to revenue and ROI, and alignment across functions including commercial, medical, regulatory, R&D, market access, insights, and tech teams.Dr Andree closes with a clear challenge for leadership: competitive advantage will come to organisations that build the most intelligent operating model around AI, not those with the biggest budgets. She also offers a 45 minute AI strategic diagnostic for pharma and biotech leaders who want an honest read on what to fix before investing further.Topics CoveredWhy pharma AI impact often disappoints despite powerful toolsThe “technical obsession trap” and the AI strategy blind spotInnovation Theatre, competitor benchmarking, and technology first mistakesWhat a pharma AI strategic blueprint must includeGovernance as a foundation for scale and regulatory trustLeadership, culture, and adoption as the real differentiatorsFinancial modelling and prioritisation based on ROI and revenue impactOrganisational alignment across the full pharma value chainChoosing the right advisory partner and avoiding generic frameworksWhy strategy must come before technology to build durable advantageAI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.Dr. Andree Bates LinkedIn | Facebook | X

As artificial intelligence becomes increasingly woven into everyday life, the real question isn’t just what AI can do — it’s what it should do for humans. In this episode, Dr Andree Bates interviews Dr Morteza Zihayat of Heisenberg Network to explore Human-Centred AI: designing intelligent systems that prioritise welfare, autonomy, dignity and trust over pure technical capability.Morteza explains how his background in data mining led to a key insight: numbers can be incredibly powerful, but they still “miss the mark” when human values are ignored. That perspective shaped his work in Human-Centred AI and helped inspire Heisenberg Network, a decentralised infrastructure designed to transform fragmented, messy data into high-quality, AI-ready intelligence — in minutes rather than weeks — while dramatically reducing cost.The conversation digs into what human-centred design looks like in practice. Morteza introduces a “ladder of priorities” to manage conflicting values — from safety and laws at the top, through ethics and platform policies, down to individual preferences — and argues that making this ladder public gives people a right to debate and appeal decisions when something feels wrong.Finally, Morteza tackles the unavoidable trade-offs between performance and fairness, sharing a real example from mental health research where reducing model accuracy produced a fairer system that clinicians felt more comfortable using. His key message is urgent: powerful AI is coming either way — making it human-centred is a choice we need to commit to now, with transparency becoming non-negotiable.Topics CoveredWhat Human-Centred AI means in practiceTurning user stories into concrete design checksThe “ladder of priorities” for managing conflicting valuesDesigning systems for welfare, autonomy, dignity and trustPower caps and keeping AI controllablePersonalisation vs wellbeing (and avoiding filter bubbles)Where bias enters: data, models, and feedback loopsDebiasing pipelines and fairness as real-world data shiftsLearning from users without storing raw personal dataExplainability challenges with reasoning modelsWhy transparency is becoming non-negotiableWhen less accuracy can be the more responsible choiceAbout the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business.Dr. Andree Bates LinkedIn | Facebook | X

Large Language Models (LLMs) are moving far beyond text generation—and into the heart of scientific discovery and pharmaceutical research. In this episode, Javier Tordable, founder and CEO of Pauling.ai and former Google technologist, explains how agentic AI systems are transforming early-stage drug discovery.Javier shares how modern LLMs differ from earlier generations, highlighting their ability to perform autonomous, multi-step scientific workflows rather than isolated tasks. These AI agents can read and synthesize massive volumes of scientific literature, generate novel hypotheses, validate ideas against published research, and accelerate computational chemistry simulations that once took months or years.The discussion dives into how LLMs are being used today to identify drug targets, design molecules, optimize clinical trials, and reduce manual scientific labor, while still preserving the critical role of human creativity and experimental validation. Javier also addresses the real risks—hallucinations, data quality, reproducibility—and why hybrid AI + physics-based approaches are essential for trustworthy results.This episode is a must-listen for researchers, founders, and operators exploring LLMs in biotech, pharma AI, scientific automation, and computational drug discovery.Topics CoveredLarge Language Models (LLMs) in science and pharmaAI agents and autonomous research workflowsEarly-stage drug discovery accelerationComputational chemistry and molecular simulationsAI-assisted literature review and hypothesis generationClinical trial optimization with AIReducing R&D timelines and operational bottlenecksRisks, hallucinations, and validation in scientific AIAbout the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more.Dr. Andree Bates LinkedIn | Facebook | Twitter

In this episode, Dr. Andre Bates, Founder & CEO of Eularis, joins Cures and Capital hosts Martin and Simona to explore how artificial intelligence is transforming drug discovery, R&D productivity, and enterprise strategy across the biopharma industry.Dr. Andre Bates shares a pragmatic view on AI in the biopharma industry, cutting through the hype to explore where AI is already delivering value and where companies need to focus for real impact. From regulatory document preparation to AI-driven drug discovery, Andre explains how AI is transforming the industry—and why human adoption is just as critical as the technology itself.What You’ll Learn from This Episode:The “low-hanging fruit” for AI in pharma, including regulatory, clinical, and medical affairs applications.How AI is accelerating drug discovery, clinical trials, and predictive healthcare.The importance of human trust and adoption in successful AI implementation.Predictions for AI-driven transformations in business models, digital twins, and disease prevention.Practical steps for building a disciplined AI strategy with measurable ROI.About the PodcastAI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget. As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses. This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more. Dr. Andree Bates LinkedIn | Facebook | Twitter